PROTEUS is a prospective randomized controlled trial within the UK's NHS, evaluating the use of AI for stress echocardiography. It aims to compare standard care to care using Artificial Intelligence to improve detection for coronary disease in patients.
The study aims to recruit 2500 participants undergoing a stress echocardiograph from 20 NHS sites around the country.
The study is funded by the NHSX Artificial Intelligence in Health and Care Award.
Coronary Artery Disease (CAD) is a leading cause of death in the UK. One of the frequent causes of inaccurate CAD diagnoses stems from image quality and expertise of the clinicians assessing it using stress echocardiography (SE), the main imaging method used to diagnose CAD. A reliable, automated method to analyse scans is therefore required to reduce variability and improve the accuracy of diagnosis.
PROTEUS is a prospective randomised controlled trial which will evaluate the use of Ultromics' EchoGo to aid clinical decision making. It processes echocardiographic images using AI, aiming to aid CAD diagnosis by taking more detailed measurements. The AI model was developed by processing images from patients who previously underwent SE exam. Analysis of its performance shows higher accuracy than clinical practice.
IRAS ID 293515 and ClinicalTrials.gov - NCT05028179
The trial will recruit 2500 adults referred for SE examination in up to 20 NHS units in the UK. Participants will be randomised (1:1) to receive either:- Standard care- Standard care with EchoGo reportParticipants will be followed-up at 3 months and 6 months after SE scan, via medical notes review and a short quality of life and symptom questionnaire. The trial will assess if using EchoGo improves patients’ clinical outcomes and improves accuracy of diagnosis.A health economic analysis will also be conducted and a qualitative sub-study will investigate attitudes of NHS stakeholders to the adoption of AI within the NHS.
Please contact the study team, email email@example.com